On Jul. 19, 2026, Samsung Biologics announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide, a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs).

Under the terms of the offer, PolyPeptide shareholders will receive CHF 44.31 in cash for each PolyPeptide share, representing an implied equity value of approximately CHF 1.46 billion. The transaction is expected to be completed towards the end of 2026, subject to customary offer conditions, including a minimum acceptance threshold of 66⅔%, applicable regulatory approvals, and other conditions described in the pre-announcement published today (Link), and the offer prospectus to be published in accordance with Swiss takeover law.

After a comprehensive review of strategic options, PolyPeptide’s Board of Directors, acting through its independent and non-conflicted members, unanimously recommend that PolyPeptide shareholders accept the tender offer, subject to the terms and conditions set forth in the offer prospectus. The Board determined that the transaction represents an attractive outcome for shareholders and PolyPeptide while positioning PolyPeptide for its next phase of growth as part of Samsung Biologics’ global CDMO platform.

With this transaction, Samsung Biologics will expand its capabilities beyond antibodies and ADCs to include peptide therapeutics, one of the fastest-growing segments of the biopharmaceutical industry, driven by surging global demand for obesity treatments and the continued expansion of peptide-based therapies into new disease areas. The transaction brings together Samsung Biologics’ global manufacturing scale with PolyPeptide’s specialized peptide expertise to create a differentiated, end-to-end multi-modality CDMO platform. PolyPeptide stands as one of the industry’s top peptide CDMOs, distinguished by its advanced technology platform and proven track record, with more than 70 years of API manufacturing heritage and over 1,000 therapeutic peptides produced to date.

PolyPeptide operates an integrated development-to-commercial model with growth focused on a modular, automation approach, giving it the flexibility to adapt quickly to changing market demand. Through PolyPeptide’s peptide capabilities, innovative technologies, and proven commercial manufacturing track record, Samsung Biologics aims to serve clients across a broader range of therapeutic modalities by addressing growing demand for peptide-based therapeutics, particularly in obesity and diabetes, including GLP-1 therapies, while advancing innovation across high-growth areas such as oncology and other emerging indications.